Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824001447 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162597949603840 |
|---|---|
| author | G. Lyrarakis S. Bouros A. Anastasopoulou A. Gkoufa P. Diamantopoulos H. Gogas D. Ziogas |
| author_facet | G. Lyrarakis S. Bouros A. Anastasopoulou A. Gkoufa P. Diamantopoulos H. Gogas D. Ziogas |
| author_sort | G. Lyrarakis |
| collection | DOAJ |
| format | Article |
| id | doaj-art-3ea0cbeab97b4e07a3196ea196ebe7cb |
| institution | OA Journals |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-3ea0cbeab97b4e07a3196ea196ebe7cb2025-08-20T02:22:32ZengElsevierEJC Skin Cancer2772-61182024-01-01210015610.1016/j.ejcskn.2024.100156Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibitionG. Lyrarakis0S. Bouros1A. Anastasopoulou2A. Gkoufa3P. Diamantopoulos4H. Gogas5D. Ziogas6National and Kapodistrian University of Athens, School of Medicine, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, Greecehttp://www.sciencedirect.com/science/article/pii/S2772611824001447 |
| spellingShingle | G. Lyrarakis S. Bouros A. Anastasopoulou A. Gkoufa P. Diamantopoulos H. Gogas D. Ziogas Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition EJC Skin Cancer |
| title | Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition |
| title_full | Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition |
| title_fullStr | Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition |
| title_full_unstemmed | Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition |
| title_short | Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition |
| title_sort | immunotherapy after progression to immunotherapy pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of pd 1 ctla 4 inhibition |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824001447 |
| work_keys_str_mv | AT glyrarakis immunotherapyafterprogressiontoimmunotherapypembrolizumabandlenvatinibversusconventionalchemotherapyforpatientswithmetastaticmelanomaafterfailureofpd1ctla4inhibition AT sbouros immunotherapyafterprogressiontoimmunotherapypembrolizumabandlenvatinibversusconventionalchemotherapyforpatientswithmetastaticmelanomaafterfailureofpd1ctla4inhibition AT aanastasopoulou immunotherapyafterprogressiontoimmunotherapypembrolizumabandlenvatinibversusconventionalchemotherapyforpatientswithmetastaticmelanomaafterfailureofpd1ctla4inhibition AT agkoufa immunotherapyafterprogressiontoimmunotherapypembrolizumabandlenvatinibversusconventionalchemotherapyforpatientswithmetastaticmelanomaafterfailureofpd1ctla4inhibition AT pdiamantopoulos immunotherapyafterprogressiontoimmunotherapypembrolizumabandlenvatinibversusconventionalchemotherapyforpatientswithmetastaticmelanomaafterfailureofpd1ctla4inhibition AT hgogas immunotherapyafterprogressiontoimmunotherapypembrolizumabandlenvatinibversusconventionalchemotherapyforpatientswithmetastaticmelanomaafterfailureofpd1ctla4inhibition AT dziogas immunotherapyafterprogressiontoimmunotherapypembrolizumabandlenvatinibversusconventionalchemotherapyforpatientswithmetastaticmelanomaafterfailureofpd1ctla4inhibition |